NovaBay Pharmaceuticals (NYSE Amex: NBY), a clinical stage biotechnology company developing first-in-class, anti-infective Aganocide® compounds for the topical treatment and prevention of antibiotic-resistant infections, will present at the 2011 Biotech Showcase Conference being held at the Parc 55 Wyndham San Francisco – Union Square. Dr. Ron Najafi, NovaBay’s Chief Executive Officer, will address attendees on Tuesday, January 11, 2011 at 11:00 AM Pacific Time.
Dr. Najafi will also participate in a panel discussion on the infectious disease landscape titled “Infectious Disease: A War on Many Fronts—Can It Be Won?”The panel discussion will take place on Wednesday, January 12, 2011 from 8:00 AM – 9:00 AM at the Parc 55 Wyndham Hotel.
Panel Discussion Overview:
On one front, viral infections have proven to be one of man’s toughest foes. While H1N1, H5N1 and SARS grab world headlines, the biotech industry is in an ongoing battle with HIV, hepatitis and the more exotic Ebola and dengue fever. On another front, bacterial infections are becoming more and more difficult to treat because of antibiotic resistance. While MRSA is best known, bacterial resistance is developing against every antibiotic in use today and solutions are still on the horizon. A panel of CEO’s developing an arsenal of next generation antiviral and antimicrobial weapons will discuss the infectious disease landscape and their technologies and targets.
More information about the 2011 Biotech Showcase Conference is available at http://www.ebdgroup.com/bts/index.php.
To arrange a meeting with NovaBay management, please contact Adam Holdsworth at 212-825-3210, or e-mail firstname.lastname@example.org.
About NovaBay’s Aganocide Compounds
NovaBay’s Aganocide compounds are novel, synthetic N-chlorinated antimicrobial molecules specifically designed and developed to mimic the body’s natural defense against infection. These compounds maintain biological activities while demonstrating improved stability over the naturally occurring N-chlorinated antimicrobial molecules. In preclinical testing, Aganocide compounds have been shown to be highly effective against bacteria, including some multi-drug resistant strains (such as MRSA), viruses and fungi. NovaBay’s Aganocide compounds have the potential to deliver the same or better efficacy than antibiotics, and to address the growing problem of antibiotic resistance by employing a novel mechanism of action.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary and patented Aganocide compounds, which are novel, synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white blood cells. NovaBay’s Aganocide compounds are being developed to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay has internal development programs aimed at addressing hospital infections, chronic non-healing wounds, urinary catheter blockage and encrustation (UCBE) and onychomycosis. The company has a license and research collaboration agreement with Alcon, Inc. for use of its Aganocide compounds to treat eye, ear and sinus infections as well as for contact lens care. NovaBay has also entered into an agreement with Galderma S.A. to develop and commercialize Aganocide compounds in acne, impetigo and other dermatological indications. For more information on NovaBay, visit:www.novabaypharma.com
NovaBay Pharmaceuticals Contacts
Thomas J. Paulson
Chief Financial Officer
Contact Thomas Paulson
The Investor Relations Group